Recent Updates
Recently added Catalysts
OVID Positive Sentiment

Manal Morsy, M.D., Ph.D., MBA

Key Takeaway: Dr. Manal Morsy has joined Ovid Therapeutics as Chief Regulatory Officer, where she will oversee global regulatory activities. With a wealth of experience in biotech and pharmaceuticals, Dr. Morsy has a proven track record of securing multiple commercial approvals. Her previous roles include leadership positions at Vaxxinity Inc. and Athersys Inc., among others.
Price reaction · baseline $3.64 (2023-09-22 close) · 10 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Morsy has extensive regulatory leadership experience.
  • She has a successful history of expediting regulatory approvals.
  • Her academic credentials include an MD, PhD, and MBA.
  • She has authored numerous publications in prestigious journals.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk

Full Press Release Details

Dr. Manal Morsy joined Ovid Therapeutics in 2025 as Chief Regulatory Officer, overseeing global regulatory activities for the company’s therapeutic programs. Dr. Morsy brings extensive regulatory leadership experience spanning biotech and pharmaceutical companies, with a highly successful history of expediting regulatory and product development paths leading to multiple commercial approvals across multiple indications, drug- and biologics-platforms. Before joining Ovid, she served as Chief Regulatory Officer, Head of Global Regulatory Affairs at Vaxxinity Inc. Prior to that, she was Executive Vice President and Head of Global Regulatory Affairs at Athersys Inc. where she tenured there for over a decade.
Earlier in her career, Dr. Morsy spent six years at PTC Therapeutics, where she served as Vice President, Global Regulatory Affairs. At PTC, she built the company’s regulatory function and led global regulatory strategy for multiple programs, including those targeting Duchenne muscular dystrophy and cystic fibrosis with Ataluren, the company’s lead product candidate.
Before joining PTC, Dr. Morsy held senior regulatory leadership positions at Tibotec / Johnson & Johnson, where she oversaw global regulatory efforts for pediatric development, tuberculosis, and HIV programs, including Prezista. She also served as Director of Worldwide Regulatory Affairs at Merck & Co., supporting new regulatory filings in the U.S. and internationally, as well as supplemental filings for approved products.
Dr. Morsy earned her MD from the University of Alexandria, Faculty of Medicine in Egypt, her PhD from Eastern Virginia Medical School/Old Dominion University, and her MBA from LeBow Business School, Drexel University. She has authored numerous scientific publications in leading peer-reviewed journals, including Nature Biotechnology, The Journal of Clinical Investigation (JCI), Proceedings of the National Academy of Sciences (PNAS), The Journal of the American Medical Association (JAMA), and Annual Review of Medicine (ARM).

Frequently Asked Questions

What position has Dr. Morsy taken at Ovid Therapeutics?

Dr. Morsy has joined Ovid Therapeutics as Chief Regulatory Officer.

What experience does Dr. Morsy bring to Ovid?

She brings extensive regulatory leadership experience from biotech and pharmaceutical companies.

Where did Dr. Morsy work before Ovid?

Prior to Ovid, she was Chief Regulatory Officer at Vaxxinity Inc.

What are Dr. Morsy's academic qualifications?

She holds an MD, PhD, and MBA from various institutions.

Last updated: Sep 23, 2023